$XRAY

HOLDEN BETSY D purchased $100K of XRAY

HOLDEN BETSY D purchased 10,086 shares of DENTSPLY SIRONA Inc. (XRAY) at $9.88 on 2026-06-11.

Original reporting
SEC EDGAR · HOLDEN BETSY D
Published Jun 15, 2026, 9:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$XRAY
Bullish
medium confidence
Mentioned
$XRAY
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XRAYBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note mild sentiment support from insider buying, but there is no fundamental catalyst described.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article provides no context on motivation, prior trading cadence, or whether the purchase is part of a broader pattern.

Relevance 4/10Novelty 5/10Timing: filed 2026-06-15 (transaction dated 2026-06-11)

Background

The article is an SEC Form 4 insider transaction disclosure for Dentsply Sirona (XRAY).

Company-level read

Ticker impact

$XRAYBullishMedium confidence
Context

Dentsply Sirona director HOLDEN BETSY D filed an open-market purchase of 10,086 shares at $9.8842 on 2026-06-11.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

This is a Form 4 insider transaction with disclosed size/price, but no accompanying operational, financial, or regulatory development is stated.

Market effects

No sector read-across; this is company-specific insider activity without new guidance or product/regulatory updates.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (e.g., diversification or personal liquidity needs) and may not signal improved fundamentals.

Key entities

  • Dentsply Sirona Inc.

    Subject of the Form 4 insider transaction disclosure (XRAY).

  • HOLDEN BETSY D

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

$XRAYMed

Dentsply Sirona Reports Strong PrimeTaper EV Results

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

$XRAYMed

DENTSPLY SIRONA Q2 Earnings Call Highlights

Dentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.

$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

$XRAYMedAI 8/10

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Dentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.